Most medicines in development today target diseases affecting large sections of the global population. However, we are now slowly beginning to see a rise in interest around developing "orphan drugs," which are pharmaceutical agents intended to treat rare diseases. The global orphan drug market is projected to increase at a compound annual growth rate (CAGR) of 12.10% between 2017 and 2025 and is expected to achieve a net valuation of US$318.5 billion by the end of 2025.
As more drug developers become interested in sponsoring an orphan drug program, it's important to understand the challenges associated with developing these drugs on an expedited timeline, as well as ways to mitigate these challenges.
Copyright © 2024 American Chemical Society | 1155 Sixteenth Street NW | Washington, DC 20036 | View our Privacy Policy